Article thumbnail
Location of Repository

The basics of preclinical drug development for neurodegenerative disease indications

By Karen L Steinmetz and Edward G Spack

Abstract

Preclinical development encompasses the activities that link drug discovery in the laboratory to initiation of human clinical trials. Preclinical studies can be designed to identify a lead candidate from several hits; develop the best procedure for new drug scale-up; select the best formulation; determine the route, frequency, and duration of exposure; and ultimately support the intended clinical trial design. The details of each preclinical development package can vary, but all have some common features. Rodent and nonrodent mammalian models are used to delineate the pharmacokinetic profile and general safety, as well as to identify toxicity patterns. One or more species may be used to determine the drug's mean residence time in the body, which depends on inherent absorption, distribution, metabolism, and excretion properties. For drugs intended to treat Alzheimer's disease or other brain-targeted diseases, the ability of a drug to cross the blood brain barrier may be a key issue. Toxicology and safety studies identify potential target organs for adverse effects and define the Therapeutic Index to set the initial starting doses in clinical trials. Pivotal preclinical safety studies generally require regulatory oversight as defined by US Food and Drug Administration (FDA) Good Laboratory Practices and international guidelines, including the International Conference on Harmonisation. Concurrent preclinical development activities include developing the Clinical Plan and preparing the new drug product, including the associated documentation to meet stringent FDA Good Manufacturing Practices regulatory guidelines. A wide range of commercial and government contract options are available for investigators seeking to advance their candidate(s). Government programs such as the Small Business Innovative Research and Small Business Technology Transfer grants and the National Institutes of Health Rapid Access to Interventional Development Pilot Program provide funding and services to assist applicants in preparing the preclinical programs and documentation for their drugs. Increasingly, private foundations are also funding preclinical work. Close interaction with the FDA, including a meeting to prepare for submission of an Investigational New Drug application, is critical to ensure that the preclinical development package properly supports the planned phase I clinical trial

Topics: Proceedings
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2697630
Provided by: PubMed Central

Suggested articles

Citations

  1. Business Administration for the US Environmental Protection Agency: Bridging the Valley of Death: Financing Technology for a Sustainable Future. Interagency Agreement
  2. (1987). Graying of America.
  3. Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products [http://www.fda.gov/downloads/Drugs/
  4. Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2(R1)
  5. Guideline for Good Clinical Practice E6(R1) [ h t t p : /
  6. (2003). PL: Bridging the Valley of Death: Transitioning from Public to Private Sector Financing
  7. (2000). Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
  8. Safety Pharmacology Studies for Human Pharmaceuticals
  9. (2007). Tapping into foundations.
  10. (1990). The 7 Habits of Highly Effective People Free Press;
  11. The target product profile as a planning tool in drug discovery research.
  12. (2007). Venture philanthropy on the rise. The CenterWatch Monthly

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.